Variant · Amplification
MAP2K4 Amplification
CI-VAR-00000250Explore in graph →CIViC 4640
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 36958197
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Uterus Leiomyosarcoma1unmapped disease | ||||||||
| MAP2K4 Amplification | PLX8725 | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID12081In two MAP2K4-amplified PDX models of uterine leiomyosarcoma, LEY-11 and LEY-16, novel MAP2K4 inhibitor PLX8725 inhibits tumor growth (PDX LEY-11 n=10, p<0.001) (PDX LEY-16 n=8 p=0.0062, n=9 p=0.001),… (full text at CIViC) PMID 36958197 · McNamara et al., 2023 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.